CR72 帖子
Muzata newly-released cable railing protector sleeves grommet is made of marine-grade T316 stainless steel. It's more convenient for you to install on corners with the ingenious single-post design. ALL you need to do is plugging the protector into the corner-drilled post with 1/8 inch stainless steel cable going through. It not only protects the wire rope from abrasion but also saves cost and presents a clean look.
Muzata newly-released cable railing protector sleeves grommet is made of marine-grade T316 stainless steel. It's more convenient for you to install on corners with the ingenious single-post design. ALL you need to do is plugging the protector into the corner-drilled post with 1/8 inch stainless steel cable going through. It not only protects the wire rope from abrasion but also saves cost and presents a clean look.
CR24 帖子
Muzata newly-released cable railing protector sleeves grommet is made of marine-grade T316 stainless steel. It's more convenient for you to install on corners with the ingenious single-post design. ALL you need to do is plugging the protector into the corner-drilled post with 1/8 inch stainless steel cable going through. It not only protects the wire rope from abrasion but also saves cost and presents a clean look.
Muzata newly-released cable railing protector sleeves grommet is made of marine-grade T316 stainless steel. It's more convenient for you to install on corners with the ingenious single-post design. ALL you need to do is plugging the protector into the corner-drilled post with 1/8 inch stainless steel cable going through. It not only protects the wire rope from abrasion but also saves cost and presents a clean look.
【Lancet Oncol:初步临床试验表明利用神经干细胞递送溶瘤病毒有望治疗恶性胶质瘤】恶性胶质瘤是成人中最常见的原发性脑肿瘤,目前没有有效的治疗方案,平均生存期为14至21个月。胶质瘤细胞是出了名的耐药性和难治性,突出了对创新和有效疗法的关键需求,这些疗法应当比化疗和放疗等传统疗法的不良副作用更少。
在一项新的1期临床研究中,来自美国西北大学医学院的研究人员开发的一种新型疗法改善了新诊断的恶性胶质瘤患者的无进展生存期和总生存期。相关研究结果近期发表在Lancet Oncology期刊上,论文标题为“Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial”。https://t.cn/A6I7hN1Z
在一项新的1期临床研究中,来自美国西北大学医学院的研究人员开发的一种新型疗法改善了新诊断的恶性胶质瘤患者的无进展生存期和总生存期。相关研究结果近期发表在Lancet Oncology期刊上,论文标题为“Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial”。https://t.cn/A6I7hN1Z
✋热门推荐